Rapport Therapeutics Analyst Price Targets - Benzinga

Rapport Therapeutics Inc

RAPPNASDAQ

Trade with Public

Trade with Public

$40.45

-1.50-3.58%

At close: Sep 18, 5:00 PM EST

$40.45

N/A

After Hours: Sep 18, 4:37 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Rapport Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rapport Therapeutics (RAPP).

Price Target Range — 8 Quarters

Analyst Consensus — 11 Analysts

2S.Buy

9Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$51Upside to Avg. PT+25.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	BTIG	Kambiz Yazdi	PT Raise	Buy	$65→$75
Aug 19, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$65
Aug 12, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$40→$66
Aug 5, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$65
Jul 16, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$65
Jun 24, 2026	Leerink Partners	Marc Goodman	Initiate	Outperform	$52
May 21, 2026	BTIG	Kambiz Yazdi	PT Raise	Buy	$53→$65
May 19, 2026	Truist Securities	Danielle Brill	Assumes	Buy	$44→$56
May 8, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$53
Apr 22, 2026	BTIG	Kambiz Yazdi	Maintained	Buy	$53
Mar 11, 2026	BTIG	Kambiz Yazdi	PT Raise	Buy	$47→$53
Mar 11, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$43→$46
Feb 2, 2026	Wells Fargo	Benjamin Burnett	Initiate	Overweight	$43
Dec 9, 2025	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$34→$40
Dec 8, 2025	BTIG	Kambiz Yazdi	Maintained	Buy	$47
Nov 19, 2025	BTIG	Kambiz Yazdi	Initiate	Buy	$47
Nov 7, 2025	Citizens	Jason N. Butler	PT Raise	Market Outperform	$77→$80
Sep 16, 2025	Truist Securities	Joon Lee	Initiate	Buy	$44
Sep 8, 2025	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$31→$34
Aug 6, 2025	HC Wainwright & Co.	Douglas Tsao	Initiate	Buy	$31

More with Benzinga EdgeGet Access

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.

Avi Kapoor

PRO
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.

Benzinga Newsdesk